BRY 812
Alternative Names: BRY-812Latest Information Update: 06 Jan 2026
At a glance
- Originator BioRay Pharmaceutical
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
- Mechanism of Action Apoprotein stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 Dec 2025 BioRay Pharmaceutical plans a phase IIa trial for Gynaecological-cancer in December 2025 (NCT07311538)
- 30 May 2025 Efficacy, adverse events and pharmacokinetic data from a phase I trial in Solid tumour presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 30 May 2025 BioRay Pharmaceuticals plans phase Ib trial in Solid tumours